Dose Escalation of Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
The aim of the study is to evaluate, after radiological progression, efficacy in patients treated with Sorafenib at a dose of 600 mg bid compared to that in patients treated with best supportive care.
Primary efficacy objective is progression free survival from randomization.
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|Official Title:||Randomized Continuation, Dose Escalation Trial of Sorafenib in Patients With Advanced HCC With Radiological Progression on Prior Sorafenib Treatment (Phase II Study)|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00490685
|Istituto Clinico Humanitas|
|Rozzano, Milan, Italy, 20089|
|Principal Investigator:||Armando Santoro, MD||Istituto Clinico Humanitas|